In accordance with Section 29 of the Securities Trading Act LifeCycle Pharma A/S (OMX: LCP) today announced that LCP has received a notification from H. Lundbeck A/S that it has decreased its shareholdings in LCP from 15,313,816 shares, corresponding to 27.21%, to 0 shares.

At the same time, LCP has received a notification that LFI A/S, 100 % owned by the Lundbeck Foundation, now owns 15,878,066 shares, corresponding to 28.21%.

About LifeCycle Pharma A/S (LCP)

Based in Horsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose(R), can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide(TM), currently on the U.S. market and a diversified near- and medium-term pipeline with five product candidates in clinical trials and one in preclinical development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.

English PDF